CClinicalTrials.gg
RecruitingNCT06409884TATUpdated May 14, 2026

Diagnosing Drug Allergy: the T is the Key

An interventional study of T-cell activation test using intracellular markers in Amoxicillin Allergy, sponsored by University Hospital, Antwerp. Recruiting at 1 site in Belgium. Open to participants aged 6 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by University Hospital, Antwerp · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to validate a newly developed test in the diagnosis of patients with amoxicillin allergy (i.e. T-cell activation test). The main questions the study aims to assess are the reliability and applicability of this test. Participants will be asked to visit the hospital 1, 3 or 5 times during which blood is collected and when applicable, allergy skin testing is performed.

Read the detailed description

Drug allergy is a significant health issue with a serious medical and financial burden of mis- and overdiagnosis. Currently applied tests differ for immediate and nonimmediate drug allergy and have variable sensitivity and specificity. Therefore, correct diagnosis remains difficult and frequently requires potentially dangerous and time-consuming challenge tests. Drug-specific T-cells play a central role in initiation and maintenance of both immediate and nonimmediate drug allergy and can be studied in the lymphocyte transformation test (LTT). However, technical difficulties have hindered entrance of the LTT in mainstream use. The investigators' data indicates that flow-based intracellular trapping and staining of markers induced during activation (such as CD154 and cytokines) enables a rapid enumeration of rare drug-specific T-cells in the blood of patients with immediate and nonimmediate amoxicillin allergy. The ambition of this project is to validate a "one fits all" assay that meets the requirements of a safe, patient friendly, accessible, and performant test that could merits the status of a primary investigation in the diagnostic algorithms. Moreover, as the tests is cost effective, it could also become an attractive method for broader applications such as the delabelling of spurious allergies. This project will focus on allergy to amoxicillin.

02

Conditions studied

  • Amoxicillin Allergy

Browse trials for

Keywords

  • Amoxicillin
  • Amoxicillin Allergy
  • Allergy
  • T-cells
03

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Participants are eligible if they:

  • Are ≥ 6 years
  • Are capable of informed consent, or if appropriate, participants have an acceptable individual capable of giving consent on the participant's behalf (e.g. parent or guardian of a child under 18 years of age)
  • Have a suspected history of amoxicillin allergy

Exclusion criteria

Exclusion Criteria:

  • Patients who are lacking capacity or do not have an acceptable individual capable to provide informed consent
  • Pregnant women
  • Breastfeeding women
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Patients with a suspected amoxicillin allergy

    Patients with a suspected amoxicillin allergy for which the diagnostic work-up was performed at the hospital for the possible diagnosis of amoxicillin allergy.

    Device: T-cell activation test using intracellular markers

Interventions

  • DeviceT-cell activation test using intracellular markers

    A blood sample will be taken which is needed for the T-cell activation test (TAT). The TAT will than be performed by trained laboratory personnel.

05

What researchers measure

Primary outcomes

  1. Sensitivity and specificity of the T-cell activation test

    Sensitivity and specificity of the T-cell activation test during Study Visit 1 of patients with amoxicillin allergy and control subjects without amoxicillin allergy.

    Time frame: Baseline

Secondary outcomes

  1. Positive predictive value (PPV) and negative predictive value (NPV), accuracy and likelihood ratio (LR)

    Positive predictive value (PPV) and negative predictive value (NPV), accuracy and likelihood ratio (LR) of the T-cell activation test in the diagnosis of amoxicillin allergy.

    Time frame: Baseline

  2. Percentage of cases with a positive TAT and positive IgE and/or skin test

    Percentage of cases with a positive TAT and positive IgE and/or skin test

    Time frame: Baseline

  3. Association between the severity of the index reaction and the performance of TAT in terms of odds ratio.

    The impact of severity of the index reaction on TAT-positivity will be studied in a logistic regression model. Odds ratios and 95% confidence intervals will be reported.

    Time frame: Baseline

  4. Association between the time since the index reaction and the performance of TAT in terms of odds ratio.

    The impact of the time since the index reaction on TAT-positivity will be studied in a logistic regression model. Odds ratios and 95% confidence intervals will be reported.

    Time frame: Basline

  5. Association between IDHR/non-IDHR and the performance of TAT in terms of odds ratio.

    The impact of IDHR/non-IDHR on TAT-positivity will be studied in a logistic regression model. Odds ratios and 95% confidence intervals will be reported.

    Time frame: Baseline

  6. Association between the severity of the index reaction and the net percentage of intracellular T-cell activation marker CD154.

    The impact of severity of the index reaction on the individual components of TAT will be studied in linear regression models, with respectively net percentage of intracellular T-cell activation markers CD154 as dependent variable. Unstandardized and standardized coefficients and standard errors will be reported.

    Time frame: Baseline

  7. Association between the severity of the index reaction and the net percentage of intracellular T-cell activation marker IL-4.

    The impact of severity of the index reaction on the individual components of TAT will be studied in linear regression models, with respectively net percentage of intracellular T-cell activation markers IL-4 as dependent variable. Unstandardized and standardized coefficients and standard errors will be reported.

    Time frame: Baseline

  8. Association between the severity of the index reaction and the net percentage of cytokine IFN-γ.

    The impact of severity of the index reaction on the individual components of TAT will be studied in linear regression models, with respectively net percentage of intracellular T-cell activation markers IFN-γ as dependent variable. Unstandardized and standardized coefficients and standard errors will be reported.

    Time frame: Baseline

  9. Association between the time since the index reaction and the net percentage of intracellular T-cell activation marker CD154.

    The impact of the time since the index reaction on the individual components of TAT will be studied in linear regression models, with respectively net percentage of intracellular T-cell activation markers CD154 as dependent variable. Unstandardized and standardized coefficients and standard errors will be reported.

    Time frame: Baseline

  10. Association between the time since the index reaction and the net percentage of intracellular T-cell activation marker IL-4.

    The impact of the time since the index reaction on the individual components of TAT will be studied in linear regression models, with respectively net percentage of intracellular T-cell activation markers IL-4 as dependent variable. Unstandardized and standardized coefficients and standard errors will be reported.

    Time frame: Baseline

  11. Association between the time since the index reaction and the net percentage of cytokine IFN-γ.

    The impact of time since the index reaction on the individual components of TAT will be studied in linear regression models, with respectively net percentage of intracellular T-cell activation markers IFN-γ as dependent variable. Unstandardized and standardized coefficients and standard errors will be reported.

    Time frame: Baseline

  12. Association between IDHR / non-IDHR and the net percentage of intracellular T-cell activation marker CD154.

    The impact of IDHR / non-IDHR on the individual components of TAT will be studied in linear regression models, with respectively net percentage of intracellular T-cell activation markers CD154 as dependent variable. Unstandardized and standardized coefficients and standard errors will be reported.

    Time frame: Baseline

  13. Association between IDHR / non-IDHR and the net percentage of intracellular T-cell activation marker IL-4.

    The impact of IDHR / non-IDHR on the individual components of TAT will be studied in linear regression models, with respectively net percentage of intracellular T-cell activation markers IL-4 as dependent variable. Unstandardized and standardized coefficients and standard errors will be reported.

    Time frame: Baseline

  14. Association between IDHR / non-IDHR and the net percentage of cytokine IFN-γ.

    The impact of IDHR / non-IDHR on the individual components of TAT will be studied in linear regression models, with respectively net percentage of intracellular T-cell activation markers IFN-γ as dependent variable. Unstandardized and standardized coefficients and standard errors will be reported.

    Time frame: Baseline

  15. Sensitivity and specificity of TAT in subgroup of cases and controls with immediate and nonimmediate reactors

    Sensitivity and specificity of T-cell activation test in a subgroup of cases and controls with immediate and nonimmediate reactors

    Time frame: Baseline

Other outcomes

  1. Sensitivity of TAT 1 year and 3 years after diagnosis

    Sensitivity of TAT 1 year and 3 years after diagnosis of patients with amoxicillin allergy

    Time frame: After 1 and 3 years

  2. Evolution TAT-components over time

    Evolution TAT-components over time in patients with amoxicillin allergy

    Time frame: After 1 and 3 years

06

Study locations

1 of 1 sites recruiting
  • Antwerp University Hospital
    Edegem, Antwerp 2650, Belgium
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06409884
Lead sponsor
University Hospital, Antwerp
Collaborators
AZ Jan Palfijn Gent, Universiteit Antwerpen
Responsible party
Sponsor
First posted
May 10, 2024
Start date
May 21, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
May 14, 2026

Study contacts

Didier Ebo, PhD
Contact
Didier.Ebo@uza.be
+3238215027
Laura Peeters, Msc
Contact
Laura.Peeters@uza.be
Didier Ebo, PhD
principal investigator · University Hospital, Antwerp

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion